Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 in Advanced Solid Cancers
NCT02648490Phase 1Completed
- Sponsor
- Henlix Biotech
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of pimurutamab in solid tumor, sponsored by Henlix Biotech. Primary endpoint: Number of participants with treatment-related adverse events at 1 year. Started Sep 2016; status: completed.
02
Drugs
pimurutamab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02648490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648490.